HONG KONG – Hong Kong-based companies Aptorum Group Ltd. and Aeneas Capital Ltd. have signed a $90 million deal with Singapore-based A*ccelerate Technologies Pte Ltd. to develop ventures in the health care and life sciences sector.
HONG KONG – Hong Kong-based companies Aptorum Group Ltd. and Aeneas Capital Ltd. have signed a $90 million deal with Singapore-based A*ccelerate Technologies Pte Ltd. to develop ventures in the health care and life sciences sector.
HONG KONG – Hutchison China Meditech Ltd. (Chi-Med) has started a phase IIb/III study for its surufatinib candidate, HMPL-012, an oral small-molecule angio-immuno kinase inhibitor that can simultaneously block tumor angiogenesis and immune evasion.
HONG KONG – Hutchison China Meditech Ltd. (Chi-Med) has started a phase IIb/III study for its surufatinib candidate, HMPL-012, an oral small-molecule angio-immuno kinase inhibitor that can simultaneously block tumor angiogenesis and immune evasion.
